Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: A 6-week randomized, double-blind, placebo-controlled trial

American Journal of Psychiatry

Volumn 172, Issue 9, 2015, Pages 870-880

  Correll, Christoph U ^a   Skuban, Aleksandar ^a   Ouyang, John ^a   Hobart, Mary ^a   Pfister, Stephanie ^a   McQuade, Robert D ^a   Nyilas, Margaretta ^a   Carson, William H ^a   Sanchez, Raymond ^a   Eriksson, Hans ^a  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREXPIPRAZOLE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROLACTIN; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; LIPID; NEUROLEPTIC AGENT; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ACUTE DISEASE; ACUTE SCHIZOPHRENIA; ADULT; AGITATION; AKATHISIA; ANXIETY DISORDER; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; HYPERSOMNIA; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; INSOMNIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC SYNDROME X; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHIZOPHRENIA; SEDATION; SOMNOLENCE; SUICIDAL IDEATION; TOXIC HEPATITIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; AKATHISIA, DRUG-INDUCED; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPIDS; MALE; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SCHIZOPHRENIA; THIOPHENES; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84937234454     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.14101275     Document Type: Article

References (35)

1. van Os J, Kapur S: Schizophrenia. Lancet 2009; 374:635-645
2. Barnes TR; Schizophrenia Consensus Group of British Association for Psychopharmacology: Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25:567-620
3. Novick D, Haro JM, Suarez D, et al: Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010; 176:109-113
4. Leucht S, Cipriani A, Spineli L, et al: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382:951-962
5. De Hert M, Detraux J, van Winkel R, et al: Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012; 8:114-126
6. Correll CU: From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010; 25(suppl 2):S12-S21
7. Kane JM, Barnes TR, Correll CU, et al: Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol 2010; 24:1019-1029
8. Maeda K, Sugino H, Akazawa H, et al: Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014; 350:589-604
9. Maeda K, Lerdrup L, Sugino H, et al: Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014; 350:605-614
10. Fleischhacker WW: Aripiprazole. Expert Opin Pharmacother 2005; 6:2091-2101
11. Sheehan DV, Janavs J, Harnett-Sheehan K, et al: Mini International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorders Studies, Version 6.0.0. https://medical-outcomes.com/
12. Kay SR, Opler LA, Fiszbein A: Positive and Negative Syndrome Scale (PANSS) Rating Criteria. North Tonawanda, NY, Multi-Health Systems, 1999
13. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: US Department of Health, Education and Welfare Publication (ADM) 76-338. Rockville, Md, National Institute of Mental Health, 1976
14. Gharabawi G, Bossie C, Turkoz I, et al: The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. J Nerv Ment Dis 2007; 195:976-982
15. Morosini PL, Magliano L, Brambilla L, et al: Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000; 101:323-329
16. Montoya A, Valladares A, Lizán L, et al: Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes 2011; 9:18
17. Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58:538-546
18. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
19. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
20. Inada T, Beasley CM Jr, Tanaka Y, et al: Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol 2003; 18:39-48
21. Posner K, Brown GK, Stanley B, et al: The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011; 168:1266-1277
22. Chappell P, Feltner DE, Makumi C, et al: Initial validityand reliability data on the Columbia-Suicide Severity Rating Scale; reply of K Posner (letter). Am J Psychiatry 2012; 169:662-663
23. Kong L, Koch G, Liu T, et al: Performance of some multiple testing procedures to compare three doses of a test drug and placebo. Pharm Stat 2005; 4:25-35
24. Huhn M, Tardy M, Spineli LM, et al: Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. JAMA Psychiatry 2014; 71:706-715
25. Leucht S, Heres S, Davis JM: Increasing placebo response in antipsychotic drug trials: let's stop the vicious circle. Am J Psychiatry 2013; 170:1232-1234
26. Alphs L, Benedetti F, Fleischhacker WW, et al: Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? Int J Neuropsychopharmacol 2012; 15:1003-1014
27. Rummel-Kluge C, Komossa K, Schwarz S, et al: Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2012; 38:167-177
28. Rummel-Kluge C, Komossa K, Schwarz S, et al: Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010; 123:225-233
29. Correll CU, Robinson DG, Schooler NR, et al: Cardiometabolic risk in first episode schizophrenia-spectrum disorder patients: baseline results from the RAISE-ETP study. JAMA Psychiatry 2014; 71:1350-1363
30. De Hert M, Yu W, Detraux J, et al: Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 2012; 26:733-759
31. Thase ME, Fava M, Hobart M, et al: Efficacy of adjunctive OPC-34712 across multiple outcome measures in major depressive disorder: a phase II, randomized, placebo-controlled study. Neuropsychopharmacology 2011; 36:S302-S304
32. Thase ME, Hobart M, Augustine C, et al: Efficacy and safety of adjunctive brexpiprazole (OPC-34712) in major depressive disorder (MDD): a phase 3, randomized, placebo-controlled study (abstract). Eur Psychiatry 2014; 29(suppl 1):EPA-0808
33. Otsuka Pharmaceutical Development & Commercialization: Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type. http://clinicaltrials.gov/ct2/show/NCT01922258?term=brexpiprazole&rank=5
34. Otsuka Pharmaceutical Development & Commercialization: A Study of Two Fixed-Doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type. http://clinicaltrials.gov/ct2/show/NCT01862640?term=brexpiprazole&rank=2
35. H Lundbeck: Brexpiprazole as an Additional Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-Traumatic Stress Disorder (PTSD). http://clinicaltrials.gov/ct2/show/NCT01987960?term=brexpiprazole&rank=10